Emerging data with 177Lu-PSMA-617 suggest that providing a greater radiation dose to the tumour may improve outcomes for patients, and this is further supported by data with other RLT agents such as 177Lu-dotatate [10, 11, 12, 13]. This evidence concerns the gene FOLH1 and neoplasm.